Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 60505-2850

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 60505-2850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Alfuzosin 01)

Chemical structure of Alfuzosin Hydrochloride, showing its molecular components and arrangement, including aromatic rings and functional groups as represented in the diagram.*

FDA Label Image

Figure-2 (Alfuzosin 03)

This line graph compares the mean change over days of treatment between placebo and Alfuzosin groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows the mean change. The Alfuzosin group (N=170) shows a greater decrease compared to the placebo group (N=167), with statistical significance indicated at the final time point.*

FDA Label Image

Figure-3 (Alfuzosin 04)

A line graph comparing mean change over days of treatment between placebo and Alfuzosin groups. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows mean change. Data points indicate a greater mean decrease in the Alfuzosin group compared to placebo, with a statistical significance marker (p < 0.01).*

FDA Label Image

Figure-4 (Alfuzosin 05)

A line chart comparing the mean change over days of treatment between Alfuzosin and placebo groups. The x-axis represents days of treatment (0, 28, 56, 84) and the y-axis shows mean change values. Alfuzosin shows a greater decrease in mean change compared to placebo, with a statistically significant difference indicated at day 84.*

FDA Label Image

Figure-5 (Alfuzosin 06)

A line graph depicting mean change in mL/s over days of treatment comparing Alfuzosin and placebo groups. The x-axis shows treatment duration in days (0, 28, 56, 84), and the y-axis shows mean change values. Alfuzosin group shows a marked increase and plateau, while the placebo group shows minimal change.*

FDA Label Image

Figure-6 (Alfuzosin 07)

A line graph comparing mean change in measured values (mL/s) over days of treatment between Placebo (dashed line with triangles) and Alfuzosin (solid line with squares). The x-axis shows days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change (0 to 3 mL/s). Alfuzosin shows higher mean changes than Placebo throughout the treatment period, with statistical significance indicated at specific points.*

FDA Label Image

Figure-7 (Alfuzosin 08)

A line graph comparing mean change in mL/s over days of treatment between placebo (N=150) and Alfuzosin (N=151). The x-axis represents days of treatment (0, 14, 28, 56, 84) and the y-axis shows mean change in mL/s. Alfuzosin shows consistently higher mean changes than placebo, with statistical significance indicated at day 84 (p < 0.001).*

FDA Label Image

Bottle 90s

Label for Alfuzosin Hydrochloride extended-release tablets, USP, 10 mg strength. The label indicates a package size of 90 tablets with NDC 60505-2850-9. The product is manufactured by Apotex Inc. in Toronto, Ontario, and for Apotex Corp. in Weston, Florida. Storage instructions and dispensing information are also included.*

FDA Label Image

Figure-1 (Uroxatral Image02)

A line graph depicting alfuzosin plasma concentration (ng/mL) over time (hours) comparing fed and fasted states. The x-axis shows time from 0 to 24 hours, and the y-axis shows plasma concentration from 0 to 14 ng/mL. Two curves represent concentration profiles for fed (higher peaks) and fasted (lower peaks) conditions, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.